Literature DB >> 16546368

Increased serum vascular endothelial growth factor levels in microscopic poly angiitis with pulmonary involvement.

Jun Iwakawa1, Wataru Matsuyama, Shingo Kubota, Hideo Mitsuyama, Takayuki Suetsugu, Masaki Watanabe, Ikkou Higashimoto, Mitsuhiro Osame, Kimiyoshi Arimura.   

Abstract

Microscopic polyangiitis (MPA) is a systemic necrotizing vasculitis that affects small vessels, resulting in a wide spectrum of organ involvement including the lungs. However, there are little serological markers that predict its prognosis or severity of pulmonary involvement. Vascular endothelial growth factor (VEGF) is an angiogenic mediator, which has been reported to be elevated in systemic vasculitis. In this study, we measured serum VEGF levels in 22 MPA patients with pulmonary involvement. We also investigated VEGF expression in pulmonary cells using flow cytometry analysis. We found that serum VEGF levels in MPA patients were significantly higher than those in respiratory or urinary tract infection. The serum VEGF levels decreased in parallel with the improvement of MPA symptoms. The serum VEGF levels in MPA patients who died within 5 years were significantly higher than those who survived more than 5 years. The sensitivity of VEGF levels to distinguish MPA patient with poor prognosis from those with good prognosis was 90.9%, and specificity was 81.8% (cutoff value = 802.5 pg/ml). The serum VEGF levels showed significant positive correlation with the composite physiological index, which indicates the severity of pulmonary lesion. In flow cytometry analysis, CD11b positive bronchoalveolar lavage fluid cells expressed VEGF. Immunohistochemically, alveolar macrophages, tissue infiltrating inflammatory cells and alveolar epithelial cells stained positive for VEGF. Measurement of serum VEGF levels in MPA might become one of the markers for prognosis and the severity of pulmonary involvement in MPA. VEGF might contribute to the development of pulmonary lesion of MPA.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16546368     DOI: 10.1016/j.rmed.2006.02.006

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  6 in total

1.  Circulating markers of vascular injury and angiogenesis in antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Paul A Monach; Gunnar Tomasson; Ulrich Specks; John H Stone; David Cuthbertson; Jeffrey Krischer; Linna Ding; Fernando C Fervenza; Barri J Fessler; Gary S Hoffman; David Ikle; Cees G M Kallenberg; Carol A Langford; Mark Mueller; Philip Seo; E William St Clair; Robert Spiera; Nadia Tchao; Steven R Ytterberg; Yi-Zhong Gu; Ronald D Snyder; Peter A Merkel
Journal:  Arthritis Rheum       Date:  2011-12

2.  Sustained monocyte activation in clinical remission of systemic vasculitis.

Authors:  Agneta Wikman; Joachim Lundahl; Stefan H Jacobson
Journal:  Inflammation       Date:  2008-12       Impact factor: 4.092

3.  Markers of endothelial damage and repair in Takayasu arteritis: are they associated with disease activity?

Authors:  Serkan Dogan; Ozden Piskin; Dilek Solmaz; Servet Akar; Aytac Gulcu; Faize Yuksel; Volkan Cakır; Ismail Sari; Nurullah Akkoc; Fatos Onen
Journal:  Rheumatol Int       Date:  2014-01-12       Impact factor: 2.631

4.  Self-vaccination by methamphetamine glycation products chemically links chronic drug abuse and cardiovascular disease.

Authors:  Jennifer Treweek; Sunmee Wee; George F Koob; Tobin J Dickerson; Kim D Janda
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-25       Impact factor: 11.205

5.  Myositis, Vasculitis, Hepatic Dysfunction in Adult-Onset Still's Disease.

Authors:  Hidekatsu Yanai; Nobuyuki Furutani; Hiroshi Yoshida; Norio Tada
Journal:  Case Rep Med       Date:  2009-06-21

Review 6.  VEGF (Vascular Endothelial Growth Factor) and Fibrotic Lung Disease.

Authors:  Shaney L Barratt; Victoria A Flower; John D Pauling; Ann B Millar
Journal:  Int J Mol Sci       Date:  2018-04-24       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.